keyword
MENU ▼
Read by QxMD icon Read
search

Stereotactic ablative

keyword
https://www.readbyqxmd.com/read/28636530/gamma-analysis-with-a-gamma-criterion-of-2-1-mm-for-stereotactic-ablative-radiotherapy-delivered-with-volumetric-modulated-arc-therapy-technique-a-single-institution-experience
#1
Jung-In Kim, Minsoo Chun, Hong-Gyun Wu, Eui Kyu Chie, Hak Jae Kim, Jin Ho Kim, Jong Min Park
To report a single-institution experience of gamma evaluations with 2%/1 mm for stereotactic ablative radiotherapy (SABR) delivered with volumetric modulated arc therapy (VMAT) technique, from January 2014 to January 2016. A total of 168 SABR VMAT plans were analyzed with a gamma criterion of 2%/1 mm, a threshold value of 10%, and a tolerance level of 90%. Of the 168 cases, four cases failed with 2%/1 mm. The average passing rate was 97.0% ± 2.5%. Three of the four failed cases showed passing rates higher than 90%, which was achieved by shifting the measuring device by 1 mm in the left-to-right or anterior-to-posterior directions...
June 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28631740/radiotherapy-for-renal-cell-carcinoma-renaissance-of-an-overlooked-approach
#2
REVIEW
Shankar Siva, Gargi Kothari, Alexander Muacevic, Alexander V Louie, Ben J Slotman, Bin S Teh, Simon S Lo
Conventional radiotherapy previously had a limited role in the definitive treatment of renal cell carcinoma (RCC), owing to the disappointing outcomes of several trials and the perceived radioresistance of this type of cancer. In this context, radiotherapy has been relegated largely to the palliation of symptoms in patients with metastatic disease, with variable rates of response. Following the availability of newer technologies that enable safe delivery of high-dose radiotherapy, stereotactic ablative radiotherapy (SABR) has become increasingly used in patients with RCC...
June 20, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28616316/what-is-the-role-of-stereotactic-ablative-radiotherapy-in-the-management-of-surgically-resectable-and-operable-stage-i-non-small-cell-lung-cancer
#3
EDITORIAL
Susannah M Love, Gillian Hardman, Ruchir Mashar, Rajesh D Shah
No abstract text is available yet for this article.
May 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28612947/stereotactic-ablative-surgery-does-not-just-mean-adding-another-lesion
#4
Marwan Hariz
No abstract text is available yet for this article.
June 14, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28612015/oligometastatic-disease-in-pancreatic-cancer-how-to-proceed
#5
REVIEW
Bernhard W Renz, Stefan Boeck, Falk Roeder, Christoph Trumm, Volker Heinemann, Jens Werner
BACKGROUND: Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or ablative treatment options for advanced-stage disease. However, highly selected patients suffering from synchronous and metachronous oligometastatic PDAC may potentially benefit from a surgical resection with an acceptable morbidity...
March 2017: Visceral Medicine
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#6
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
June 13, 2017: Digestion
https://www.readbyqxmd.com/read/28592286/immunological-effect-of-local-ablation-combined-with-immunotherapy-on-solid-malignancies
#7
REVIEW
Yusuke Takahashi, Noriyuki Matsutani, Takashi Nakayama, Hitoshi Dejima, Hirofumi Uehara, Masafumi Kawamura
Recent comprehensive investigations clarified that immune microenvironment surrounding tumor cells are deeply involved in tumor progression, metastasis, and response to treatment. Furthermore, several immunotherapeutic trials have achieved successful results, and the immunotherapeutic agents are available in clinical practice. To enhance their demonstrated efficacy, combination of immunotherapy and ablation has begun to emerge. Local ablations have considerable advantages as an alternative therapeutic option, especially its minimal invasiveness...
June 7, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28591482/hypothalamic-hamartoma-epileptogenesis-beyond-the-lesion
#8
Julia Scholly, Anke Maren Staack, Philippe Kahane, Didier Scavarda, Jean Régis, Edouard Hirsch, Fabrice Bartolomei
The discovery of intrinsic epileptogenicity of the hypothalamic hamartoma (HH) marked a new area in understanding the associated clinical syndrome, often manifesting as progressive epileptic encephalopathy. However, therapeutic procedures targeting the HH proved to be inefficient to cure seizures in up to 50% of cases, whereas in cases with partial improvement, the electroclinical patterns of persisting seizures suggest an involvement of distant cortical regions. The concept of kindling-like secondary epileptogenesis has been suggested as a possible underlying mechanism...
June 2017: Epilepsia
https://www.readbyqxmd.com/read/28591480/laser-interstitial-thermal-therapy-a-first-line-treatment-for-seizures-due-to-hypothalamic-hamartoma
#9
Victor X Du, Shashank V Gandhi, Harold L Rekate, Ashesh D Mehta
Successful treatment of hypothalamic hamartoma (HH) can result in the resolution of its sequelae including epilepsy and rage attacks. Risks and morbidity of open surgical management of this lesion have motivated the development of laser interstitial thermal therapy (LITT) as a less invasive treatment approach to the disease. Although overall morbidity and risk would appear to be lower, complications related to LITT therapy have been reported, and the longer-term follow-up that is now possible after initial experience helps address the question of whether LITT provides equivalent efficacy compared to other treatment options...
June 2017: Epilepsia
https://www.readbyqxmd.com/read/28590814/a-dosimetric-parameter-to-limit-chest-wall-toxicity-in-sabr-of-nsclc
#10
Raphaël Jumeau, Édith Filion, Houda Bahig, Toni Vu, Louise Lambert, David Roberge, Robert Doucet, Marie-Pierre Campeau
OBJECTIVE: Chest wall (CW) toxicity (rib fracture and/or pain) is a recognized complication of stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the frequency of CW toxicity following SABR and to propose a new dosimetric parameter. METHODS: We reviewed the charts and SABR plans from patients treated for T1-T2N0 peripheral NSCLC between 2009 and 2015. The CW structure was created through a 3 cm expansion of the lung...
June 7, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28587057/safety-and-efficacy-of-stereotactic-ablative-radiation-therapy-for-renal-cell-carcinoma-extracranial-metastases
#11
Chiachien Jake Wang, Alana Christie, Mu-Han Lin, Matthew Jung, Derek Weix, Lorel Huelsmann, Kristin Kuhn, Jeffrey Meyer, Neil Desai, D W Nathan Kim, Ivan Pedrosa, Vitaly Margulis, Jeffrey Cadeddu, Arthur Sagalowsky, Jeffrey Gahan, Aaron Laine, Xian-Jin Xie, Hak Choy, James Brugarolas, Robert Timmerman, Raquibul Hannan
PURPOSE: Renal cell carcinoma is refractory to conventional radiation therapy but responds to higher doses per fraction. However, the dosimetric data and clinical factors affecting local control (LC) are largely unknown. We aimed to evaluate the safety and efficacy of stereotactic ablative radiation therapy (SAbR) for extracranial renal cell carcinoma metastases. METHODS AND MATERIALS: We reviewed 175 metastatic lesions from 84 patients treated with SAbR between 2005 and 2015...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28587012/stereotactic-ablative-body-radiation-for-pulmonary-metastases-should-we-consider-dose-escalation-for-more-unresponsive-histologies
#12
Q N Nguyen, Y Lu, C Tang, W W Chance, R Mehran, P Balter, J W Welsh, S M Hahn, M D Jeter, R U Komaki, D R Gomez, J Y Chang, Z Liao
No abstract text is available yet for this article.
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28587009/mediastinal-hilar-stereotactic-ablative-radiation-therapy-for-primary-and-oligorecurrent-non-small-cell-lung-cancer
#13
Z D Horne, A Richman, D A Clump, S A Burton, J D Luketich, D E Heron
No abstract text is available yet for this article.
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28581406/long-term-survival-analysis-of-stereotactic-ablative-radiotherapy-versus-liver-resection-for-small-hepatocellular-carcinoma
#14
Ting-Shi Su, Ping Liang, Jian Liang, Huan-Zhen Lu, Hua-Yan Jiang, Tao Cheng, Yong Huang, Yang Tang, Xin Deng
PURPOSE: To compare the efficacy of stereotactic ablative radiation therapy (SABR) versus liver resection for small hepatocellular carcinoma (HCC) ≤5 cm with Child-Pugh A cirrhosis. METHODS AND MATERIALS: This retrospective study included 117 patients with small HCCs with 1 or 2 nodules. Eighty-two patients received SABR (SABR group), and 35 patients underwent liver resection (resection group). Overall survival (OS) and progression-free survival (PFS) were analyzed...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28581404/treatment-related-toxicity-in-patients-with-early-stage-non-small-cell-lung-cancer-and-coexisting-interstitial-lung-disease-a-systematic-review
#15
REVIEW
Hanbo Chen, Suresh Senan, Esther J Nossent, R Gabriel Boldt, Andrew Warner, David A Palma, Alexander V Louie
PURPOSE: Definitive treatment for patients with early-stage non-small cell lung cancer (ES-NSCLC) is usually well tolerated. Patients with ES-NSCLC and coexisting interstitial lung disease (ILD) are at increased risk of severe treatment-related toxicity after definitive therapy. The main objective of this systematic review is to provide a pooled estimation of treatment-related mortality and ILD-specific toxicity in this population of patients and to identify trends for further study. METHODS AND MATERIALS: The MEDLINE and Embase databases were queried from respective dates of inception to January 2016...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28580377/optimization-of-curvilinear-needle-trajectories-for-transforamenal-hippocampotomy
#16
David B Comber, E Bryn Pitt, Hunter B Gilbert, Matthew W Powelson, Emily Matijevich, Joseph S Neimat, Robert J Webster, Eric J Barth
BACKGROUND: The recent development of MRI-guided laser-induced thermal therapy (LITT) offers a minimally invasive alternative to craniotomies performed for tumor resection or for amygdalohippocampectomy to control seizure disorders. Current LITT therapies rely on linear stereotactic trajectories that mandate twist-drill entry into the skull and potentially long approaches traversing healthy brain. The use of robotically-driven, telescoping, curved needles has the potential to reduce procedure invasiveness by tailoring trajectories to the curved shape of the ablated structure and by enabling access through natural orifices...
February 2017: Operative Neurosurgery (Hagerstown, Md.)
https://www.readbyqxmd.com/read/28577830/stereotactic-ablative-body-radiotherapy-for-lung-metastases-where-is-the-evidence-and-what-are-we-doing-with-it
#17
REVIEW
Shankar Siva, Ben J Slotman
This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577829/stereotactic-ablative-radiotherapy-for-early-stage-lung-cancer
#18
REVIEW
Jennifer L Shah, Billy W Loo
The rising incidence of early-stage lung cancer, particularly in medically inoperable patients, is anticipated because of the implementation of early detection strategies and population aging in the United States and worldwide. This mandates the development of noninvasive curative treatment approaches for this disease. Stereotactic ablative radiotherapy (SABR) has recently emerged as a standard of care for early-stage lung cancer in medically inoperable patients who cannot safely tolerate surgical lobectomy, the established standard for operable patients...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577828/stereotactic-body-radiotherapy-in-the-treatment-of-spinal-metastases
#19
REVIEW
Evangelia Katsoulakis, Kiran Kumar, Ilya Laufer, Yoshiya Yamada
Patients with metastatic disease including polymetastatic, oligometastatic, and oligorecurrent spinal lesions have extended life expectancy secondary to improvements in systemic agents, and thus require durable local control of spine metastases. Stereotactic body radiotherapy (SBRT), which uses highly conformal treatment planning techniques coupled with image-guided technology, has enabled the safe delivery of tumor-ablative doses of radiotherapy. The NOMS decision framework has been developed as a tool to aid in the determination of the optimal treatment of spinal metastases, incorporating radiosurgery, separation surgery, stabilization techniques, and conventional radiation...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577827/normal-tissue-constraints-for-abdominal-and-thoracic-stereotactic-body-radiotherapy
#20
REVIEW
Erqi L Pollom, Alexander L Chin, Maximilian Diehn, Billy W Loo, Daniel T Chang
Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology, experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites...
July 2017: Seminars in Radiation Oncology
keyword
keyword
12178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"